Back to top
more

Relay Therapeutics (RLAY)

(Real Time Quote from BATS)

$7.65 USD

7.65
215,044

-0.34 (-4.26%)

Updated Aug 2, 2024 10:31 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 11.43% and 2,905.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 146.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 131.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Inotiv, Inc. (NOTV) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inotiv, Inc. (NOTV) delivered earnings and revenue surprises of -957.14% and 0.56%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Xencor (XNCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 189.21%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to an 189.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 202.33% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 202.3% upside potential for Relay Therapeutics, Inc. (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 127.27% and 155.31%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -3.85% and 69.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -11.43% and 42.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 94.78%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 94.8% in Relay Therapeutics, Inc. (RLAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of 21.13% and 66.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Relay Therapeutics, Inc. (RLAY) Q4 Earnings Expected to Decline

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lannett (LCI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lannett (LCI) delivered earnings and revenue surprises of 17.07% and 10.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.90% and 4.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?